CN102762102A - 新的噁二唑化合物 - Google Patents
新的噁二唑化合物 Download PDFInfo
- Publication number
- CN102762102A CN102762102A CN2010800633803A CN201080063380A CN102762102A CN 102762102 A CN102762102 A CN 102762102A CN 2010800633803 A CN2010800633803 A CN 2010800633803A CN 201080063380 A CN201080063380 A CN 201080063380A CN 102762102 A CN102762102 A CN 102762102A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- bases
- diazole
- chloro
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COc(ccc(-c1nc(*)n[o]1)c1)c1OC1CCCC1 Chemical compound COc(ccc(-c1nc(*)n[o]1)c1)c1OC1CCCC1 0.000 description 11
- IIOBMSQAWGDCAV-YLIDJSGBSA-N C/C=C\C=C(\CN(Cc1ccccc1)[C@@H](CC1)CC1(C(OC)=O)F)/C=C Chemical compound C/C=C\C=C(\CN(Cc1ccccc1)[C@@H](CC1)CC1(C(OC)=O)F)/C=C IIOBMSQAWGDCAV-YLIDJSGBSA-N 0.000 description 1
- DAEYLFIGUTZQEP-UHFFFAOYSA-N CC(C)C(C)c1ccc(C(C)N)cc1 Chemical compound CC(C)C(C)c1ccc(C(C)N)cc1 DAEYLFIGUTZQEP-UHFFFAOYSA-N 0.000 description 1
- UJBLTJFOPUZBAG-YMBRHYMPSA-N CC(C)Cc(cc1)ccc1-c1nc(-c(cc2)ccc2NC(CC2)C[C@@H]2C(O)=O)n[o]1 Chemical compound CC(C)Cc(cc1)ccc1-c1nc(-c(cc2)ccc2NC(CC2)C[C@@H]2C(O)=O)n[o]1 UJBLTJFOPUZBAG-YMBRHYMPSA-N 0.000 description 1
- YRUVRUJGBRXMKN-UHFFFAOYSA-N CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c(cc2)ccc2S(NCC(O)=O)(=O)=O)n1 Chemical compound CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c(cc2)ccc2S(NCC(O)=O)(=O)=O)n1 YRUVRUJGBRXMKN-UHFFFAOYSA-N 0.000 description 1
- BVLPEBRNLWOVSJ-UHFFFAOYSA-N CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c2c(C)[n](CCN(CC(OC(C)(C)C)=O)C3)c3n2)n1 Chemical compound CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c2c(C)[n](CCN(CC(OC(C)(C)C)=O)C3)c3n2)n1 BVLPEBRNLWOVSJ-UHFFFAOYSA-N 0.000 description 1
- ZXXNJGWHPCGJPS-UHFFFAOYSA-N CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c2c(C)[n](CCNC3)c3n2)n1 Chemical compound CC(C)Oc(c(Cl)c1)ccc1-c1n[o]c(-c2c(C)[n](CCNC3)c3n2)n1 ZXXNJGWHPCGJPS-UHFFFAOYSA-N 0.000 description 1
- UOVQZIZXOMPHLV-UHFFFAOYSA-N CC(C)Oc(c(Cl)c1)ccc1C1=N[U]C(c(cc2)ccc2S(NCC(OC(C)(C)C)=O)(=O)=O)=N1 Chemical compound CC(C)Oc(c(Cl)c1)ccc1C1=N[U]C(c(cc2)ccc2S(NCC(OC(C)(C)C)=O)(=O)=O)=N1 UOVQZIZXOMPHLV-UHFFFAOYSA-N 0.000 description 1
- CDCMREXKACZRJJ-UHFFFAOYSA-N CC(C)Oc(cc1)c(C(F)(F)F)cc1-c1n[o]c(-c(cc2)ccc2F)n1 Chemical compound CC(C)Oc(cc1)c(C(F)(F)F)cc1-c1n[o]c(-c(cc2)ccc2F)n1 CDCMREXKACZRJJ-UHFFFAOYSA-N 0.000 description 1
- QUBVFMMPRUOGDO-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2F)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2F)n1)c1)c1Cl QUBVFMMPRUOGDO-UHFFFAOYSA-N 0.000 description 1
- TXNRKMRYTAXUBC-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2NC(CC2)CC2(C(O)=O)O)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2NC(CC2)CC2(C(O)=O)O)n1)c1)c1Cl TXNRKMRYTAXUBC-UHFFFAOYSA-N 0.000 description 1
- MZZYKNSMCLHJHC-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2S(NCCC(O)=O)(=O)=O)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c(cc2)ccc2S(NCCC(O)=O)(=O)=O)n1)c1)c1Cl MZZYKNSMCLHJHC-UHFFFAOYSA-N 0.000 description 1
- DQDHRZULMPTEGR-MRTLOADZSA-N CC(C)Oc(ccc(-c1n[o]c(-c(cc2C#C)ccc2NC(CC2)C[C@@H]2C(O)=O)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c(cc2C#C)ccc2NC(CC2)C[C@@H]2C(O)=O)n1)c1)c1Cl DQDHRZULMPTEGR-MRTLOADZSA-N 0.000 description 1
- SJHIDFFSOITJIF-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c(cc2C#C[SiH-](C)(C)C)ccc2F)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c(cc2C#C[SiH-](C)(C)C)ccc2F)n1)c1)c1Cl SJHIDFFSOITJIF-UHFFFAOYSA-N 0.000 description 1
- BYLQYHJAGOVETR-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c2cc(C#N)ccc2)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c2cc(C#N)ccc2)n1)c1)c1Cl BYLQYHJAGOVETR-UHFFFAOYSA-N 0.000 description 1
- ZILSQRUSTYTWOM-QHCPKHFHSA-N CC(C)Oc(ccc(-c1n[o]c(-c2ccc([C@@](C)(N(CC(O)=O)CC(O)=O)O)cc2)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c2ccc([C@@](C)(N(CC(O)=O)CC(O)=O)O)cc2)n1)c1)c1Cl ZILSQRUSTYTWOM-QHCPKHFHSA-N 0.000 description 1
- MVNVESFSBOXWAN-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c2ccc3[nH]ccc3c2)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c2ccc3[nH]ccc3c2)n1)c1)c1Cl MVNVESFSBOXWAN-UHFFFAOYSA-N 0.000 description 1
- BQDQGJAZEDVFGK-UHFFFAOYSA-N CC(C)Oc(ccc(-c1n[o]c(-c2cccc(C(NO)=N)c2)n1)c1)c1Cl Chemical compound CC(C)Oc(ccc(-c1n[o]c(-c2cccc(C(NO)=N)c2)n1)c1)c1Cl BQDQGJAZEDVFGK-UHFFFAOYSA-N 0.000 description 1
- ANZGGNVJAGOJSL-UHFFFAOYSA-N CC(C)Oc(nc1)c(C)cc1/C(/N)=N/O Chemical compound CC(C)Oc(nc1)c(C)cc1/C(/N)=N/O ANZGGNVJAGOJSL-UHFFFAOYSA-N 0.000 description 1
- DXAAGKSRRUZRJL-UHFFFAOYSA-N CC(C)Oc(ncc(C#N)c1)c1Cl Chemical compound CC(C)Oc(ncc(C#N)c1)c1Cl DXAAGKSRRUZRJL-UHFFFAOYSA-N 0.000 description 1
- RZSMDXXNWPSPPX-UHFFFAOYSA-N CC(C)Oc(ncc(C(ONC)=N)c1)c1Cl Chemical compound CC(C)Oc(ncc(C(ONC)=N)c1)c1Cl RZSMDXXNWPSPPX-UHFFFAOYSA-N 0.000 description 1
- HYUZZQIAJWNRAQ-UHFFFAOYSA-N CC(COCc1ccccc1)N Chemical compound CC(COCc1ccccc1)N HYUZZQIAJWNRAQ-UHFFFAOYSA-N 0.000 description 1
- ZIXSIWGHSYGNFI-WRSRUZKNSA-N CCC(C)[C@H](CC1)CC1Nc(c(C#C)c1)ccc1-c1nc(-c(cc2)cc(Cl)c2OC(C)C)n[o]1 Chemical compound CCC(C)[C@H](CC1)CC1Nc(c(C#C)c1)ccc1-c1nc(-c(cc2)cc(Cl)c2OC(C)C)n[o]1 ZIXSIWGHSYGNFI-WRSRUZKNSA-N 0.000 description 1
- CVBLNNNHPBYDIV-UHFFFAOYSA-N CCOC(C(CC1)(CC1O)NC(OC(C)(C)C)=O)=O Chemical compound CCOC(C(CC1)(CC1O)NC(OC(C)(C)C)=O)=O CVBLNNNHPBYDIV-UHFFFAOYSA-N 0.000 description 1
- ROEGCCATJNZPFL-WCQYABFASA-N CCOC([C@@H](CC1)C[C@@H]1Nc(cc1)ccc1/C(/N)=N/O)=O Chemical compound CCOC([C@@H](CC1)C[C@@H]1Nc(cc1)ccc1/C(/N)=N/O)=O ROEGCCATJNZPFL-WCQYABFASA-N 0.000 description 1
- DFFZMZLYAOFJAR-GXTWGEPZSA-N CCOC([C@@H](CC1)C[C@@H]1Nc(cc1)ccc1C#N)=O Chemical compound CCOC([C@@H](CC1)C[C@@H]1Nc(cc1)ccc1C#N)=O DFFZMZLYAOFJAR-GXTWGEPZSA-N 0.000 description 1
- LWNMKCSIQOTKJD-UHFFFAOYSA-N CCOC(c1c(C)nc2[n]1ccnc2)O Chemical compound CCOC(c1c(C)nc2[n]1ccnc2)O LWNMKCSIQOTKJD-UHFFFAOYSA-N 0.000 description 1
- YCKSVMGCZVWUCM-UHFFFAOYSA-N COC(C1(CCCC1)F)=O Chemical compound COC(C1(CCCC1)F)=O YCKSVMGCZVWUCM-UHFFFAOYSA-N 0.000 description 1
- FBNZJDYBWJYLRY-UHFFFAOYSA-N COC(C1)=NCCN1C(OCc1ccccc1)=O Chemical compound COC(C1)=NCCN1C(OCc1ccccc1)=O FBNZJDYBWJYLRY-UHFFFAOYSA-N 0.000 description 1
- IIHIJFJSXPDTNO-UHFFFAOYSA-N COC(C1CCCC1)=O Chemical compound COC(C1CCCC1)=O IIHIJFJSXPDTNO-UHFFFAOYSA-N 0.000 description 1
- UGGVQIFZODXSAW-UHFFFAOYSA-N Cc1ccc(C(O)O)c(OC)c1 Chemical compound Cc1ccc(C(O)O)c(OC)c1 UGGVQIFZODXSAW-UHFFFAOYSA-N 0.000 description 1
- GGYOTWNYQIPODS-UHFFFAOYSA-N Cc1cnc(C2)[n]1CCN2C(OCc1ccccc1)=O Chemical compound Cc1cnc(C2)[n]1CCN2C(OCc1ccccc1)=O GGYOTWNYQIPODS-UHFFFAOYSA-N 0.000 description 1
- CQZQCORFYSSCFY-UHFFFAOYSA-N N#Cc(cc1C(F)(F)F)ccc1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1F CQZQCORFYSSCFY-UHFFFAOYSA-N 0.000 description 1
- MGHMXYNQCUCXCJ-UHFFFAOYSA-N N#Cc1cc(-c2ccccc2)c(C(F)(F)F)[s]1 Chemical compound N#Cc1cc(-c2ccccc2)c(C(F)(F)F)[s]1 MGHMXYNQCUCXCJ-UHFFFAOYSA-N 0.000 description 1
- IQDNWHBWAHHWPT-UHFFFAOYSA-N N#Cc1cc(-c2nc(-c(cc3)ccc3F)n[o]2)ccc1N(CC1)CCC1F Chemical compound N#Cc1cc(-c2nc(-c(cc3)ccc3F)n[o]2)ccc1N(CC1)CCC1F IQDNWHBWAHHWPT-UHFFFAOYSA-N 0.000 description 1
- DGJGKOXILJMZLV-UHFFFAOYSA-N N/C(/c(cc1C(F)(F)F)ccc1F)=N/O Chemical compound N/C(/c(cc1C(F)(F)F)ccc1F)=N/O DGJGKOXILJMZLV-UHFFFAOYSA-N 0.000 description 1
- BQYHGXUXZIGKCO-UHFFFAOYSA-N N=Cc1cc(C=O)ccc1F Chemical compound N=Cc1cc(C=O)ccc1F BQYHGXUXZIGKCO-UHFFFAOYSA-N 0.000 description 1
- SJEZCKCLCOQOEQ-UHFFFAOYSA-N NC(c1cc(-c2ccccc2)c(C(F)(F)I)[s]1)=O Chemical compound NC(c1cc(-c2ccccc2)c(C(F)(F)I)[s]1)=O SJEZCKCLCOQOEQ-UHFFFAOYSA-N 0.000 description 1
- MLLSSTJTARJLHK-UHNVWZDZSA-N N[C@@H](CC1)C[C@@H]1C(O)=O Chemical compound N[C@@H](CC1)C[C@@H]1C(O)=O MLLSSTJTARJLHK-UHNVWZDZSA-N 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N Nc1nccnc1 Chemical compound Nc1nccnc1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- OFOUHYPGPMJFHX-UHFFFAOYSA-N O=Cc(cc1C2=NC2)ccc1F Chemical compound O=Cc(cc1C2=NC2)ccc1F OFOUHYPGPMJFHX-UHFFFAOYSA-N 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N OC(C1CCCC1)=O Chemical compound OC(C1CCCC1)=O JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Oc(cc1)ccc1C(OCc1ccccc1)=O Chemical compound Oc(cc1)ccc1C(OCc1ccccc1)=O MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26767909P | 2009-12-08 | 2009-12-08 | |
US61/267,679 | 2009-12-08 | ||
PCT/US2010/046424 WO2011071570A1 (fr) | 2009-12-08 | 2010-08-24 | Composés inédits d'oxadiazole |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102762102A true CN102762102A (zh) | 2012-10-31 |
Family
ID=44145850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800633803A Pending CN102762102A (zh) | 2009-12-08 | 2010-08-24 | 新的噁二唑化合物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2509424A4 (fr) |
JP (1) | JP2013512951A (fr) |
CN (1) | CN102762102A (fr) |
AR (1) | AR077908A1 (fr) |
CA (1) | CA2783851A1 (fr) |
MX (1) | MX2012006667A (fr) |
TW (1) | TW201120016A (fr) |
UY (1) | UY32853A (fr) |
WO (1) | WO2011071570A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260173A (zh) * | 2021-04-30 | 2022-11-01 | 厦门宝太生物科技股份有限公司 | 环戊烷并吲哚类支链酸衍生物及其制备方法和应用 |
CN116444454A (zh) * | 2023-06-16 | 2023-07-18 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE036519T2 (hu) | 2007-08-13 | 2018-07-30 | Monsanto Technology Llc | Készítmények és eljárások nematódák irtására |
WO2013036530A1 (fr) | 2011-09-08 | 2013-03-14 | Allergan, Inc. | Modulateurs de récepteurs de 3-(4-(5-phényl-1,2,4-oxadiazol-3-yl)phénoxy)propan-2-ol en tant que modulateurs de récepteurs de sphingosine-1-phosphate |
PT2970236T (pt) | 2013-03-15 | 2017-11-30 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-4-ilo |
CN107614491A (zh) * | 2014-06-26 | 2018-01-19 | 蒙纳什大学 | 酶相互作用剂 |
US20220041572A1 (en) * | 2018-09-18 | 2022-02-10 | Bristol-Myers Squibb Company | Cycloheptyl acids as lpa antagonists |
CN113473985A (zh) * | 2018-09-18 | 2021-10-01 | 百时美施贵宝公司 | 作为lpa拮抗剂的环戊酸 |
CN109369620B (zh) * | 2018-12-22 | 2020-04-14 | 山东大学 | 吡啶类化合物及其制备方法与抗胃癌应用 |
CN109776443B (zh) * | 2019-03-25 | 2022-09-27 | 上海万巷制药有限公司 | 一种具有抗氧化作用的噁二唑类化合物及其制备方法 |
KR20220104000A (ko) | 2019-11-19 | 2022-07-25 | 모다크 게엠베하 | 알파-시누클레인의 응집과 관련된 질병의 진단, 치료 및 예방을 위한 신규한 화합물 |
UY38964A (es) | 2019-11-25 | 2021-06-30 | Novartis Ag | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas |
CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
WO2023118253A1 (fr) * | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dérivés d'acide cyclohexane utilisés en tant qu'inhibiteurs du récepteur de lpa |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
WO2007132307A1 (fr) * | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Dérivés d'acide cycloalkylaminé et compositions pharmaceutiques à base de ceux-ci |
EP2069335B1 (fr) * | 2006-09-08 | 2012-12-26 | Actelion Pharmaceuticals Ltd. | Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
NZ588439A (en) * | 2008-03-07 | 2012-05-25 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
GB0911130D0 (en) * | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
-
2010
- 2010-08-20 TW TW099128025A patent/TW201120016A/zh unknown
- 2010-08-23 AR ARP100103076A patent/AR077908A1/es unknown
- 2010-08-23 UY UY0001032853A patent/UY32853A/es not_active Application Discontinuation
- 2010-08-24 MX MX2012006667A patent/MX2012006667A/es not_active Application Discontinuation
- 2010-08-24 EP EP10836346.6A patent/EP2509424A4/fr not_active Withdrawn
- 2010-08-24 WO PCT/US2010/046424 patent/WO2011071570A1/fr active Application Filing
- 2010-08-24 JP JP2012543093A patent/JP2013512951A/ja not_active Withdrawn
- 2010-08-24 CN CN2010800633803A patent/CN102762102A/zh active Pending
- 2010-08-24 CA CA2783851A patent/CA2783851A1/fr not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260173A (zh) * | 2021-04-30 | 2022-11-01 | 厦门宝太生物科技股份有限公司 | 环戊烷并吲哚类支链酸衍生物及其制备方法和应用 |
CN116444454A (zh) * | 2023-06-16 | 2023-07-18 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
CN116444454B (zh) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
Also Published As
Publication number | Publication date |
---|---|
TW201120016A (en) | 2011-06-16 |
MX2012006667A (es) | 2012-10-15 |
UY32853A (es) | 2011-06-30 |
EP2509424A1 (fr) | 2012-10-17 |
CA2783851A1 (fr) | 2011-06-16 |
EP2509424A4 (fr) | 2013-09-04 |
WO2011071570A1 (fr) | 2011-06-16 |
AR077908A1 (es) | 2011-09-28 |
JP2013512951A (ja) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102762102A (zh) | 新的噁二唑化合物 | |
CN101562977A (zh) | 新的二唑化合物 | |
CN110312719B (zh) | 作为jak家族激酶抑制剂的咪唑并吡咯并吡啶 | |
JP7489381B2 (ja) | Il-12、il-23および/またはifnアルファの調節に関連する疾患を治療するためのアミド置換ヘテロ環化合物 | |
CN104370909B (zh) | 三环化合物 | |
CN105829305B (zh) | Nrf2调节剂 | |
CN103402996B (zh) | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 | |
CN101553224A (zh) | 新型咪唑并噻唑和咪唑并唑 | |
SG172982A1 (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof | |
US20090069288A1 (en) | Novel therapeutic compounds | |
US20110207704A1 (en) | Novel Oxadiazole Compounds | |
TW201700453A (zh) | Ido抑制劑 | |
WO2008079382A1 (fr) | Composés d'agonistes et d'antagonistes des récepteurs de sphingosine-1-phosphate | |
CN104592231A (zh) | 新的三环化合物 | |
US8217027B2 (en) | Sphingosine-1-phosphate receptor agonist and antagonist compounds | |
TW201617331A (zh) | 異吲哚啉衍生物 | |
CN106795147A (zh) | 作为β‑分泌酶抑制剂的环丙基稠合噻嗪‑2‑胺化合物和使用方法 | |
JP2022508953A (ja) | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 | |
CN101610674A (zh) | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 | |
JP2018519354A (ja) | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 | |
WO2024088408A1 (fr) | Composé hétérocyclique contenant de l'azote, sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121031 |